Quantcast

Industry news that matters to you.  Learn more

Biodesix’ GeneStrat Blood-Based Mutation Test Now Includes EML4-ALK Fusions

Biodesix, Inc. recently announced that the GeneStrat™ blood-based panel now includes EML4-ALK fusions in addition to EGFR sensitizing, EGFR T790M, KRAS, and BRAF mutations. GeneStrat is a non-invasive, blood-based test analyzing circulating tumor DNA and RNA, designed to provide fast, accurate results in 72 hours for newly diagnosed non-small cell lung cancer (NSCLC) patients.

Biodesix Launches GeneStrat Targeted Liquid Biopsy Mutation Test For Patients With Advanced Lung Cancer

Biodesix, Inc. recently announced the launch of GeneStrat™, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC). The blood test results are available within 72 hours, providing physicians actionable diagnostic information prior to making treatment decisions. GeneStrat is focused exclusively on the clinically actionable EGFR, KRAS, and BRAF mutations often used to guide targeted therapy treatment decisions. GeneStrat also captures the EGFR T790M mutation, which can be used for monitoring the emergence of the primary resistance mutation in the EGFR gene. It is anticipated that two drugs targeting the resistance mutation may be available later this year. GeneStrat uses the ddPCR platform to analyze cell-free tumor DNA and is highly concordant with tissue analysis, currently considered the gold standard.

IntegraGen Announces Publication of Study with Biomarker Associated with Survival in Metastatic Colorectal Cancer Patients Treated with Drug Therapy

IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, recently announced the publication of a study in Clinical Cancer Research which reports on the ability of the microRNA (miRNA) miR-31-3p to predict progression-free survival in KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor (EGFR) antibodies.

Large International Tumor Profiling Study of Colorectal Cancer Provides Key Treatment Insights for World’s Third Most Common Cancer

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, recently presented a large international tumor profiling study of colorectal cancer at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence™ the study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer. Colorectal cancer (CRC) is the third most common cancer worldwide, with metastatic disease accounting for 40 to 50 percent of newly diagnosed patients.

Multiplicom Launches Three New Mutation Detection Kits to Enable the Implementation of Personalized Cancer Treatment

Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing (MPS), recently announced that it is launching three new somatic mutation detection kits which will enable users to implement personalized cancer treatment at an unprecedented level.